Skip to main content
    C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.08
    -0.27 (-4.25%)

    Market Cap: $193.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cartesian Therapeutics Inc. (RNAC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Cartesian Therapeutics reported revenue of $2.80M for the fiscal year ended Dec 31, 2025, down 92.8% from the year before. That year, net income was -$130.30M with a net margin of -4658.6%, operating cash flow was -$73.94M and free cash flow was -$79.39M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$11.47M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $8.08M, a compound annual decline of 11.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.80M-92.8%100.0%-5127.1%-4658.6%
    Dec 2024$38.91M+49.6%100.0%-112.8%-199.0%
    Dec 2023$26.00M-76.5%100.0%-332.3%-844.9%
    Dec 2022$110.78M+30.2%100.0%13.1%31.9%
    Dec 2021$85.08M+412.6%100.0%-5.4%-30.2%
    Dec 2020$16.60M+148.6%100.0%-342.4%-415.0%
    Dec 2019$6.68M+639.4%100.0%-785.6%-829.0%
    Dec 2018$903.00K+336.2%100.0%-7200.7%-7235.4%
    Dec 2017$207.00K-97.4%100.0%-30813.5%-31556.0%
    Dec 2016$8.08MN/A100.0%-428.9%-448.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.80M$38.91M$26.00M$110.78M$85.08M$16.60M$6.68M$903.00K$207.00K$8.08M
    Gross profit$2.80M$38.91M$26.00M$110.78M$85.08M$16.60M$6.68M$903.00K$207.00K$8.08M
    Research and development$58.03M$45.10M$71.26M$72.38M$68.74M$54.51M$42.74M$47.69M$45.16M$29.70M
    Operating income-$143.41M-$43.90M-$86.42M$14.54M-$4.60M-$56.82M-$52.45M-$65.02M-$63.78M-$34.67M
    Net income-$130.30M-$77.42M-$219.71M$35.38M-$25.69M-$68.88M-$55.35M-$65.34M-$65.32M-$36.21M
    EBITDA-$143.12MN/AN/A$36.31M-$4.51MN/AN/A-$64.03M-$62.92M-$34.59M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$78.00K$947.00K$452.00K$298.00K$1.10M-$759.00K$387.00K$33.45M$5.84M$8.27M
    Gross profit$0$0$78.00K$947.00K$452.00K$298.00K$1.10M-$759.00K$387.00K$33.45M$5.84M$8.27M
    Operating income-$25.00M-$29.16M-$26.50M-$78.64M-$21.07M-$21.81M-$21.89M-$26.73M-$17.57M$13.76M-$13.35M-$36.33M
    Net income-$11.47M$15.77M-$39.18M-$92.58M-$35.90M$15.89M-$17.71M-$10.25M-$24.18M$13.84M-$56.82M-$177.66M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $4.15M by $120.99M. Shareholder equity was negative, at -$126.24M, as total liabilities of $422.65M exceeded total assets of $296.41M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$296.41M$435.02M$305.05M$165.89M$159.88M$165.44M$99.57M$44.48M$101.10M$89.30M
    Current assets$129.28M$216.63M$90.73M$148.14M$144.44M$151.34M$96.67M$42.08M$98.68M$86.82M
    Cash and equivalents$125.14M$212.61M$76.91M$106.44M$114.06M$138.69M$89.89M$37.40M$70.70M$58.66M
    Total liabilities$422.65M$441.82M$444.68M$72.06M$137.36M$183.44M$91.17M$49.90M$47.46M$34.34M
    Short-term debt$4.15M$2.85M$2.17M$8.48M$5.96M$0$18.91M$21.39M$0$4.07M
    Long-term debt$0N/AN/A$17.79M$19.67M$24.79M$0$0$21.04M$7.98M
    Shareholder equity-$126.24M-$6.80M-$440.18M$93.83M$22.52M-$18.01M$8.40M-$5.42M$53.64M$54.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$294.31M$318.63M$288.39M$296.41M$372.68M$388.89M$409.13M$435.02M$455.32M$347.74M$325.21M$305.05M
    Total liabilities$424.77M$443.85M$436.51M$422.65M$408.52M$391.42M$430.92M$441.82M$454.56M$449.20M$442.01M$745.23M
    Cash and equivalents$122.97M$147.61M$118.64M$125.14M$143.38M$160.32M$180.43M$212.61M$219.20M$87.23M$103.42M$76.91M
    Shareholder equity-$130.47M-$125.23M-$148.12M-$126.24M-$35.84M-$2.53M-$21.79M-$6.80M$752.00K-$101.46M-$116.80M-$440.18M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$73.94M-$23.67M-$51.16M-$31.63M-$60.38M$34.88M-$51.44M-$59.16M-$52.03M-$19.76M
    Capital expenditures$5.45M$9.09M$206.00K$1.20M$1.08M$815.00K$47.00K$884.00K$733.00K$586.00K
    Free cash flow-$79.39M-$32.77M-$51.37M-$32.83M-$61.47M$34.07M-$51.48M-$60.05M-$52.76M-$20.34M
    Dividends paid$7.75M$0N/AN/AN/A$184.00K$28.00KN/A$25.45M$4.57M
    Share repurchases$624.00K$66.00K$0N/AN/AN/AN/AN/AN/A$4.10M
    Investing cash flow-$5.45M-$8.74M$34.61M-$15.00M-$17.14M-$741.00K$229.00K$25.27M-$2.10M-$22.10M
    Financing cash flow-$8.05M$168.43M-$13.14M$39.22M$52.90M$14.43M$105.04M$697.00K$66.02M$67.66M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$27.73M-$21.08M-$22.14M-$17.71M-$15.60M-$17.52M-$23.11M-$7.00M$13.69M-$14.45M-$15.92M-$23.29M
    Capital expenditures$441.00K$272.00K$27.00K$492.00K$1.29M$2.60M$1.07M$705.00K$6.20M$1.59M$602.00K$64.00K
    Free cash flow-$28.17M-$21.35M-$22.16M-$18.20M-$16.89M-$20.12M-$24.18M-$7.71M$7.49M-$16.03M-$16.52M-$23.35M
    Last 12 quarters

    Frequently Asked Questions About RNAC

    What is Cartesian Therapeutics' annual revenue?

    Cartesian Therapeutics reported revenue of $2.80M for the fiscal year ended Dec 31, 2025.

    How fast is Cartesian Therapeutics' revenue growing?

    Revenue was down 92.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -70.7%.

    Is Cartesian Therapeutics profitable?

    No. Cartesian Therapeutics reported net income of -$130.30M for the fiscal year ended Dec 31, 2025, with a net margin of -4658.6%.

    How much free cash flow does RNAC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$73.94M minus capital expenditures of $5.45M produced free cash flow of -$79.39M.

    How much debt does Cartesian Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $4.15M and cash and equivalents of $125.14M.